 Takeda Pharmaceutical Co Ltd NYSE:TAK announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to safety issues. Following the suspension of this promising pipeline, the companys growth recovery prospects appear dismal, according to BofA Securities. 